Crizotinib, first-in-class amongst the ALK and ROS inhibitors, is still a very effective and safe option for the treatment of patients with ALK positive metastatic NSCLC, a condition associated with a poor prognosis and for which limited therapeutic options exist. This evidence concerns the gene ALK and non-small cell lung carcinoma.